Sherry X. Yang

Dr. Sherry X. Yang

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
NTNaoko Takebe
Naoko Takebe
DNDat Nguyen
Dat Nguyen
SYSherry X. Yang
Sherry X. Yang

1 April 2016 in Cancer Treatment Reviews
Verified
Journal Article
Open access
SYSherry X. Yang
Sherry X. Yang
EPEric Polley
Eric Polley
SLStanley Lipkowitz
Stanley Lipkowitz
PI3K/AKT signaling pathway plays an important role in tumorigenesis and regulates critical cellular functions including survival, proliferation and metabolism. PIK3CA mutations and AKT activation by phosphorylation (pAKT) are often detected in many cancers and especially at high frequencies in breast cancer. Mounting data suggest that PIK3CA mutations or pAKT are mostly associated with better or insignificant outcomes in estrogen receptor-positive (ER+) early stage breast cancer and tend to be with worse prognosis in ER- disease. pAKT expression has been identified to predict paclitaxel chemotherapy benefit in node-positive breast cancer. Preclinical and neoadjuvant trial data suggest that PIK3CA alterations confer resistance to HER2-targeted therapy and are associated with lower pathological complete response (pCR) rate in HER2-positive breast cancer. However, recent results from randomized clinical trials of adjuvant and metastatic settings show that patients with mutant and wildtype PIK3CA tumors derived similar benefit from anti-HER2 therapy. This article, with our new insights, aims to decipher the mixed data and discusses the influence of the potential confounding factors in the assessments. We also share our views for validation of PI3K/AKT alterations in relation to clinical outcome in the context of specific breast cancer subtypes and treatment modalities towards further advance of the precision medicine for breast cancer treatment.

12 April 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ALAngelo B. A. Laranjeira
Angelo B. A. Laranjeira
MHMelinda G. Hollingshead
Melinda G. Hollingshead
DNDat Nguyen
Dat Nguyen
RKRobert J. Kinders
Robert J. Kinders
JDJames H. Doroshow
James H. Doroshow
SYSherry X. Yang
Sherry X. Yang
Role of DNA damage and demethylation on anticancer activity of DNA methyltransferase inhibitors (DNMTi) remains undefined. We report the effects of DNMT1 gene deletion/disruption (DNMT1−/−) on anticancer activity of a class of DNMTi in vitro, in vivo and in human cancers. The gene deletion markedly attenuated cytotoxicity and growth inhibition mediated by decitabine, azacitidine and 5-aza-4′-thio-2′-deoxycytidine (aza-T-dCyd) in colon and breast cancer cells. The drugs induced DNA damage that concurred with DNMT1 inhibition, subsequent G2/M cell-cycle arrest and apoptosis, and upregulated p21 in DNMT1+/+ versus DNMT1−/− status, with aza-T-dCyd the most potent. Tumor growth and DNMT1 were significantly inhibited, and p21 was upmodulated in mice bearing HCT116 DNMT1+/+ xenograft and bladder PDX tumors. DNMT1 gene deletion occurred in ~ 9% human colon cancers and other cancer types at varying degrees. Decitabine and azacitidine demethylated CDKN2A/CDKN2B genes in DNMT1+/+ and DNMT1−/− conditions and increased histone-H3 acetylation with re-expression of p16INK4A/p15INK4B in DNMT1−/− state. Thus, DNMT1 deletion confers resistance to DNMTi, and their anti-cancer activity is determined by DNA damage effects. Patients with DNMT1 gene deletions may not respond to DNMTi treatment.

1 December 2011 in Cell Cycle
Verified
Journal Article
Closed access
DNDiana Nguyen
Diana Nguyen
MZMaria Zajac-Kaye
Maria Zajac-Kaye
LRLarry Rubinstein
Larry Rubinstein
DVDonna Voeller
Donna Voeller
JTJoseph E. Tomaszewski
Joseph E. Tomaszewski
SYSherry X. Yang
Sherry X. Yang
Targeting DNA repair with poly(ADP-ribose) polymerase (PARP) inhibitors has shown a broad range of anti-tumor activity in patients with advanced malignancies with and without BRCA deficiency. It re...

5 April 2022 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
SYSherry X. Yang
Sherry X. Yang
SHStephen M Hewitt
Stephen M Hewitt
JYJohn Yu
John Yu
The role of lymph node involvement and tumor size in metastatic disease including breast cancer is unclear. Here, nodal metastasis and T stage on the risk of mortality were investigated in de novo metastatic breast cancer population (35812 patients) in the Surveillance, Epidemiology, and End Results (SEER) Program database in the United States. We found an association between all-cause mortality and regional node involvement (adjusted hazard ratio [HR] = 1.45, 95% confidence interval [CI] 1.36–1.55, p < 0.0001) or T stage (HR = 1.20, 95% CI 1.14–1.25, p < 0.0001), independent of known clinicopathologic measurements. Number of positive nodes, and size and chest wall involvement of the breast tumors exhibited similar significance for breast cancer-specific mortality in the population (p < 0.0001 each), and all-cause mortality in hormone receptor (HR)-positive/HER2-negative (HR+/HER2–), HR+/HER2+, HR–/HER2+ and triple-negative metastatic breast cancer subtypes. Thus, nodal involvement and T stage are independent risk factors for mortality in the population of de novo metastatic breast cancer.

1 July 2020 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
DNDat Nguyen
Dat Nguyen
JYJohn Yu
John Yu
WRWilliam C. Reinhold
William C. Reinhold
SYSherry X. Yang
Sherry X. Yang
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related death for women in the United States. Current guidelines by the National Comprehensive Cancer Network and American Society of Clinical Oncology recommend management with endocrine therapy, ERBB2- (formerly HER2-) (OMIM 164870) directed therapy, radiotherapy, and cytotoxic chemotherapy or a combination for patients with invasive breast cancer.1 The choice of treatment modality depends on patient and tumor characteristics, expression of hormone receptors (HR; including estrogen receptor α [ER] or progesterone receptor [PR]), and ERBB2 status as well as genomic test results such as the Oncotype DX breast recurrence score.2 Endocrine therapy with a duration of 5 to 10 years is a standard of care for HR-positive disease, which accounts for approximately 70% of all breast cancers.3-5 Radiotherapy applies to all individuals who underwent breast-conserving surgery and may be used for patients with a tumor larger than 5 cm or with node-positive disease after mastectomy. Chemotherapy is recommended for patients with ERBB2-positive and HR-negative tumors, node-positive disease, and high Oncotype recurrence scores in HR-positive and ERBB2-negative breast cancer.3,6